指南与共识心脑血管急症重症综合管理与镇静镇痛

左心瓣膜病合并心源性休克的经导管介入治疗:EAPCI与ACVC及ESC心血管外科工作组共识声明

Transcatheter interventions for left-sided valvular heart disease complicated by cardiogenic shock: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) in collaboration with the Association for Acute Cardiovascular Care (ACVC) and the ESC Working Group on Cardiovascular Surgery.
指南 / 共识 · EuroIntervention · 2023-01-01
一句话结论国际专家组共识:左心瓣膜病合并心源性休克时,经导管瓣膜介入可能是有前景的替代方案,但支持证据稀少,现行指南无具体推荐。

该共识由欧洲经皮心血管介入协会(EAPCI)科学文件与倡议委员会邀请国际专家组制定,联合急性心血管监护协会(ACVC)和ESC心血管外科工作组发布。左心瓣膜病是心力衰竭常见原因,合并心源性休克时死亡风险极高,外科治疗常被认为风险过高。经导管瓣膜介入创伤较小,可能成为有前景的替代方案,但支持性科学证据 scarce,多限于小样本病例系列,现行瓣膜病指南无具体推荐。共识旨在综述现有证据,为该临床情境下经导管瓣膜介入的应用提供依据和实践方法。

要点

  • 左心瓣膜病合并心源性休克死亡风险极高,外科治疗常被认为风险过高。
  • 经导管瓣膜介入创伤较小,可能是有前景的替代方案,但支持证据 scarce,多限于小样本病例系列。
  • 现行瓣膜病指南未包含针对瓣膜病合并心源性休克患者管理的具体推荐。
  • 共识由EAPCI科学文件与倡议委员会邀请国际专家组制定,联合ACVC和ESC心血管外科工作组发布。
  • 共识旨在综述现有证据,并为经导管瓣膜介入在该特定临床情境的应用提供依据和实践方法。

适用人群与场景

  • 左心瓣膜病合并心源性休克的患者。
  • 外科治疗常被认为风险过高的患者。

研究设计与关键结果

  • 共识由EAPCI科学文件与倡议委员会邀请的国际专家组制定,联合ACVC和ESC心血管外科工作组发布。
  • 左心瓣膜病是心力衰竭最常见原因之一,保守治疗患者预后差。
  • 经导管瓣膜介入的适应证已从无法手术/高危患者扩展至较年轻/较低危患者。
  • 左心瓣膜病合并心源性休克死亡风险极高,外科治疗常被认为风险过高。
  • 经导管瓣膜介入创伤较小,可能是有前景的替代方案,但支持性科学证据 scarce,多限于小样本病例系列。
  • 现行瓣膜病指南未包含针对瓣膜病合并心源性休克患者管理的具体推荐。

证据类型、等级与局限

  • 证据类型:临床共识声明(指南/共识)。
  • 支持经导管瓣膜介入用于左心瓣膜病合并心源性休克的科学证据 scarce,多限于小样本病例系列。
  • 现行瓣膜病指南未包含针对该临床情境的具体推荐。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 共识旨在为左心瓣膜病合并心源性休克患者应用经导管瓣膜介入提供依据和实践方法。
  • 原文未据此给出具体推荐。

指南或共识出处

  • 欧洲经皮心血管介入协会(EAPCI)与急性心血管监护协会(ACVC)及ESC心血管外科工作组的共识声明,发表于EuroIntervention。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Valvular heart disease (VHD) is one of the most frequent causes of heart failure (HF) and is associated with poor prognosis, particularly among patients with conservative management. The development and improvement of catheter-based VHD interventions have broadened the indications for transcatheter valve interventions from inoperable/high-risk patients to younger/lower-risk patients. Cardiogenic shock (CS) associated with severe VHD is a clinical condition with a very high risk of mortality for which surgical treatment is often deemed a prohibitive risk. Transcatheter valve interventions might be a promising alternative in this setting given that they are less invasive. However, supportive scientific evidence is scarce and often limited to small case series. Current guidelines on VHD do not contain specific recommendations on how to manage patients with both VHD and CS. The purpose of this clinical consensus statement, developed by a group of international experts invited by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Scientific Documents and Initiatives Committee, is to perform a review of the available scientific evidence on the management of CS associated with left-sided VHD and to provide a rationale and practical approach for the application of transcatheter valve interventions in this specific clinical setting.

来源:EuroIntervention,查看原文。版权归原作者所有。

参考来源

  1. Fraccaro C, Karam N, Möllmann H, et al. Transcatheter interventions for left-sided valvular heart disease complicated by cardiogenic shock: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) in collaboration with the Association for Acute Cardiovascular Care (ACVC) and the ESC Working Group on Cardiovascular Surgery. EuroIntervention. 2023. PMID: 37624587. doi:10.4244/EIJ-D-23-00473

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。